Pharmaceutical / Drug Definition :
Augments antiemetic activity of ondansetron (a 5-hydroxytryptamine3-receptor antagonist) and dexamethasone. Also inhibits cisplatin-induced emesis.
In the United States, Aprepitant is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Aprepitant.
Registrar Corp assists Aprepitant companies with:
FDA Label Requirements and Exceptions
FDA Import Information
Aprepitant (Aprepitant Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Aprepitant (Aprepitant Suppliers)
- Processors Aprepitant
- Repackers Aprepitant
- Relabelers Aprepitant
- Exporters Aprepitant
- Importers Aprepitant
For more information about Aprepitant, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.